The world’s only surgical robot company covering the five “golden tracks” is from Zhangjiang, Shanghai
Xinmin Evening News (Reporter Ma Yaning) Surgical robots have high clinical value, which can effectively improve the accuracy and stability of surgery, shorten the postoperative recovery period of patients, and reduce the occurrence of complications; it can effectively shorten the learning curve of doctors and reduce the number of surgeons. Radiation exposure… At present, the only surgical robot company in the world covering the five “golden tracks” of laparoscopy, orthopedics, pan-vascular, natural orifice and percutaneous puncture is from Zhangjiang, Shanghai. It is MicroPort Medical Science Co., Ltd. and its subsidiary, Shanghai MicroPort Medical Robot (Group) Co., Ltd., was successfully listed on the main board of the Hong Kong Stock Exchange.
As the global surgical robot industry continues to mature, the surgical robot market is showing rapid growth. According to statistics, the global surgical robot market size will increase from US$3 billion in 2015 to US$8.3 billion in 2020, and may reach US$33.6 billion in 2026. In China, the surgical robot market is still in the early stage of development, and the market penetration rate is extremely low. The size of the Chinese surgical robot market in 2020 is only US$400 million. However, China has a large number of patients and a strong demand for minimally invasive surgery, and the growth potential is huge. It is expected to reach 3.8 billion US dollars in 2026. At the same time, the proportion of China’s surgical robot market in the global market is expected to increase from 5% in 2020 to 2026. 11% of the global market.
As an internal incubation project of MicroPort®, the research and development project of surgical robots was established in 2014. In 2015, MicroPort® Robotics Company was officially established. Sophisticated research and industrial integration in the field of information provide innovative solutions for robotic intelligent surgery that can prolong and reshape life, and build a globalized innovation platform for solutions to medical robots. At present, after years of R&D innovation and industrial accumulation, MicroPort® Robot has developed into a group operating company that masters the underlying technology of the entire chain of surgical robots, with multi-disciplinary integration and platforms for optics, mechanics, electricity, control, software, computing, and imaging. It has built a comprehensive surgical robot technology innovation platform and a sound industrialized operation system, covering research and development, clinical trials, registration, and supply chain management.
According to reports, the product portfolio of MicroPort® robots includes one approved product and eight pipeline products. The company’s three flagship products, the Toumai® Laparoscopic Surgical Robot, the Dragonfly Eye® DFVision® 3D Electronic Laparoscopic Endoscope and the Honghu® Orthopaedic Surgery Navigation and Positioning System, have all entered the State Drug Administration’s special approval process for innovative medical devices (” Green Channel”), and Dragonfly Eye® has been approved by the State Food and Drug Administration in June 2021. At the same time, MicroPort® Robots is also actively conducting strategic cooperation around the world, establishing partnerships with many top international surgical robot companies; and accelerating the deployment of R&D centers in Singapore and other overseas countries and regions, making full use of global R&D resources , attract the world’s top talents, carry out overseas registration and market promotion, and build an international innovation platform with deep integration of technology research and development and industrial integration.
Dr. He Chao, President of MicroPort® Robotics, said, “The listing on the Hong Kong Stock Exchange will provide sufficient financial support for our continuous expansion and layout in the five ‘golden tracks’. In the future, we will further explore and innovate and accelerate research and development. With the progress of industrialization and industrialization, we will continue to provide patients in China and around the world with solutions for robotic intelligent surgery that can prolong and reshape their lives.”